myeloproliferative disorders
Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative disorders (MPD).
Developing <span class="gene" id="22087750-1-11-25">Janus kinase 2</span> (<span class="gene" id="22087750-1-27-31">Jak2</span>) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a <span class="gene" id="22087750-1-165-169">Jak2</span> gain-of-function mutation in the majority of patients with <span class="disease" id="22087750-1-229-257">myeloproliferative disorders</span> (MPD).